Comparison of rivaroxaban and enoxaparin in the prevention of recurrent venous thromboembolism

Phase 3

Recruiting

• Conditions: onhematologic Cancers.; Embolism and thrombosis of unspecified artery; I74.9

• Registration Number: IRCT20201123049469N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 January 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Existence of active cancer with Venous thromboembolism
The age range is between 18-75 years
Tendency to participate in the study

Exclusion Criteria

Smoking, alcohol and drug abuse
Lack of sufficient and appropriate evidence for the occurrence of early Venous thromboembolism
Diagnosis of thrombophilic conditions
Prescribe any anticoagulant drug excepting Enoxaparin or Rivaroxaban (for example Heparin, Warfarin, Dabigatran, Apixaban, and Edoxaban)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Recurrence of VTE (Venous thromboembolism) is deep vein thromboembolism (DVT) or pulmonary embolism (PE) according to the report of CT scan of the pulmonary arteries and color Doppler ultrasound of the lower extremity to be reported by the radiologist. Timepoint: At the beginning of the study (before the intervention) and 6 months later. Method of measurement: according to the report of CT scan of the pulmonary arteries and color Doppler ultrasound of the lower extremity to be reported by the radiologist.